Decompensated hepatitis B virus-related cirrhosis successfully treated with lamivudine allowing surgery for hepatocellular carcinoma

Internal Medicine

Volumn 42, Issue 5, 2003, Pages 416-420

  Nakanishi, Seiji ^a   Michitaka, Kojiro ^a   Miyake, Teruki ^a   Hidaka, Satoshi ^a   Yoshino, Itaru ^a   Konishi, Ichiro ^a   Iuchi, Hidehito ^a   Horiike, Norio ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hepatitis B virus; Hepatocellular carcinoma; Lamivudine

Indexed keywords

DIURETIC AGENT; LAMIVUDINE;

ABDOMINAL ANGIOGRAPHY; ADULT; ARTICLE; ASCITES; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG EFFECT; HEPATITIS B; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; JAUNDICE; LABORATORY TEST; LAPAROSCOPY; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; PARTIAL HEPATECTOMY; PHYSICAL EXAMINATION;

EID: 0038174744     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.416     Document Type: Article

References (12)

1. Ichida T, Iwatsuki S, Kakumu S. UNOS-selection criteria and order of priority for the candidate of liver transplantation. Nippon Shokakibyo Gakkai Zasshi 98: 1-7, 2001 (in Japanese).
2. Coates JA, Cammack N, Jenkinson HJ, et al. (-)-2′-deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 36: 733-739, 1992.
3. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119: 172-180, 2000.
4. Villeneuve JP, Condreay LD, Willems B, et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 31: 207-210, 2000.
5. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 33: 301-307, 2000.
6. Kapoor D, Guptan RC, Wakil SM, et al. Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 33: 308-312, 2000.
7. Honkoop P, de Man RA, Zondervan PE, Schalm SW. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine. Liver 17: 103-106, 1997.
8. Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 339: 61-68, 1998.
9. Suzuki Y, Kumada H, Ikeda K, et al. Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 30: 743-748, 1999.
10. Yao FY, Terrault NA, Freise C, Maslow L, Bass NM. Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology 34: 411-416, 2001.
11. Kitay-Cohen Y, Ben-Ari Z, Tur-Kaspa R, Fainguelernt H, Lishner M. Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis. Transplantation 69: 2382-2383, 2000.
12. Bruno R, Sacchi P, Filice C, Filice G. Acute liver failure during lamivudine treatment in a hepatitis B cirrhotic patient. Am J Gastroenterol 96: 265, 2001.